A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata

← catalyst calendar

NCT07772492 · readout ≤ 2,050 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

300estimated

Sites

Countries

Australia, France, Israel +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-08-30

estimated

When the study began enrolling

Primary completion

Mar 2032

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2032

estimated

The whole study's end, after follow-up

First posted

2026-08-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Severe Alopecia Areata

Interventions

Drug: Upadacitinib
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20, defined as less than or equal to 20% scalp hair loss.

measured At Week 24

Number of Participants with Adverse Events (AEs)

measured Up to Week 160

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed